Leukemia team building

The Leukemia & Lymphoma Society has announced its first research partnership with a large biopharma company-a four-year, multimillion-dollar deal with Celgene Corp. to solicit and fund proposals from academics and smaller biotechs. The not-for-profit organization expects the deal's framework to serve as a template for future collaborations and is in talks with additional big biotech and pharma companies.

In its first year, the partnership will support up to 10 projects that explore basic disease mechanisms underlying hematological malignancies and up to 2 product development programs for advanced preclinical or early stage clinical candidates. Celgene will provide all research funding and will have right of first negotiation on any IP resulting from the projects.

"Over the last five years we've been partnering with biotech companies in earnest through the Therapy Acceleration Program, where we look for small companies that have assets

Read the full 1389 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE